Trial Profile
An open label, randomized, phase 2 study of Paclitaxel and Panitumumab compared to Paclitaxel alone in patients with relapsed or refractory urothelial cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2018
Price :
$35
*
At a glance
- Drugs Panitumumab (Primary) ; Paclitaxel
- Indications Adenocarcinoma; Bladder cancer; Squamous cell cancer; Urogenital cancer
- Focus Therapeutic Use
- 12 Dec 2018 Status changed from recruiting to discontinued.
- 23 Dec 2015 New trial record